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Abstract
Background: Lower estimated glomerular filtration rate (eGFR) has been associated with an increased risk of major vascular
events (MVEs) and death, but differences in methodology make between-study comparisons difficult. We used a novel
method to summarise the published results.
Methods and Findings: Studies assessing the relationship between baseline eGFR and subsequent MVEs or all cause
mortality were identified using Pubmed. Those which involved at least 500 individuals, planned at least 1 year of follow-up,
reported age and sex adjusted relative risks, and provided the mean eGFR in each category (or sufficient information to
allow its estimation) were included. To take account of differences in underlying risk between studies, proportional within-
study differences in eGFR (rather than absolute eGFR values) were related to risk. Fifty studies (2 million participants)
assessing MVEs and 67 studies (5 million participants) assessing all cause mortality were eligible. There was an inverse
relationship between lower eGFR and the risk of MVEs and of death. In studies among people without prior vascular disease,
a 30% lower eGFR level was on average associated with a 29% (SE 0.2%) increase in the risk of a MVE and a 31% (SE 0.2%)
increase in the risk of death from any cause. In studies among people with prior vascular disease, these estimates were 26%
(SE 1.0%) and 23% (SE 0.2%) respectively. While there was substantial statistical heterogeneity between the results of
individual studies, a 30% lower eGFR was consistently associated with a 20-30% higher risk of both outcomes, irrespective of
prior history of vascular disease or study design.
Conclusions: Lower eGFR was consistently associated with a moderate increase in the risk of death and MVEs. If these
relationships are causal and continuous, then around one fifth of vascular events among those over 70 years might be
attributable to renal impairment.
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Introduction
Individuals requiring dialysis treatment have a 10 to 100 fold
increased risk of vascular death compared with the general
population [1], but represent less than 0.2% of the population [2].
In contrast, mild-to-moderate reductions in estimated glomerular
filtration rate (eGFR) are common, especially among older people.
In the United States, for example, only about 2% of people aged
40-59 years have an eGFR ,60 ml/min/1.73 m
2 but this
proportion increases to about 25% among those aged over 70
years [3]. Several prospective cohort studies have suggested that
such mild-to-moderate reductions in eGFR may be associated with
a moderate, but clinically important, increase in the risk of major
vascular events [4–7] and also of the overall risk of death [8], but
this has not been a consistent finding in all populations studied [9-
14].
We sought to perform a meta-analysis of the observational
relationship between eGFR and the risk of major vascular events
and mortality. In order to provide a meta-analytic summary of
these relationships from studies with reference and disease groups
which differed widely in their chosen cut points of eGFR, we
developed a novel technique in which the published measures of
relative effect in each study, adjusted as completely as possible for
confounding, were related to the corresponding relative differences
in mean eGFR between the disease and reference groups. This
method minimises any biases resulting from variations in the
creatinine assay [15] or the use of different equations to estimate
GFR, because such biases ‘drop out’ of the mathematical
calculations involved in relative comparisons.
Methods
Data sources and searches
Studies that had reported relationships between estimated
glomerular filtration rate (eGFR), and major vascular events
(MVEs), mortality, or both, were identified with a Pubmed search
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st September 2008). We used a combination of terms
relating to vascular disease or death, creatinine or eGFR, and
cohort studies (Appendix S1), and supplemented this electronic
search with review of reference lists from subsequently retrieved
papers and, where appropriate, contact with study authors. Only 3
studies [17–19] reported vascular and non-vascular mortality
separately, so analyses are limited to assessing associations between
eGFR and all-cause mortality. Studies were included if eGFR was
estimated by the Modification of Diet in Renal Disease (MDRD)
study [20] or the Cockcroft-Gault [21] formulae. For each study
we aimed to identify a composite outcome, MVE, that involved a
combination of one or more of: myocardial infarction, unstable
angina, stroke, transient ischaemic attack, coronary or non
coronary revascularisation, or vascular, cardiac or coronary death.
Study selection
Studies involving at least 500 individuals and 1 year of follow-up
were eligible if they reported an age- and sex-adjusted association
between eGFR and all-cause mortality, eGFR and MVEs, or both.
Studies were included if they were conducted among apparently
healthy individuals, among patients with known prior vascular
disease or among individuals with an increased risk of vascular
disease (e.g. patients with hypertension). Studies in populations
with pre-existing chronic kidney disease (CKD) or serious non-
vascular disease were excluded. We included studies only if the
publication reported a relevant association in terms of a
comparison between two or more categories of individuals defined
by eGFR cut-points (eg, a relative risk corresponding to
comparison between those with eGFR ,60ml/min/1.73m
2 and
those with eGFR $60ml/min/1.73m
2).
Data extraction and quality assessment
We extracted, from each study, details of the study population,
mean follow-up, the type and total number of outcomes, the cut
points used, the mean eGFR, the number of individuals and
outcomes in each eGFR category, confounding variables for which
adjustment had been made in the most complete regression model,
and relative risks and confidence intervals for each relevant
comparison under that model. A non-randomised study was
classified as a ‘‘prospective cohort study’’ if the baseline data were
collected prospectively, with contemporaneous assessment of
clinical measurements and laboratory blood tests using standard-
ised methods. In most of these studies, participants were actively
followed up at study visits or by telephone or postal questionnaire
with subsequent confirmation of major vascular events using
hospital records. A study which extracted data from health care
records retrospectively was classified as a ‘‘retrospective cohort
study’’. If separate reports were available from a single study
population, the first published paper was used unless a subsequent
report contained additional events. In studies where ‘‘pooled’’
analyses had been performed in the original papers [6;22;23],
authors were asked to provide study-specific results. In one major
study in which age-specific analyses were performed, the authors
were contacted to provide separate age-specific and overall results
for people with or without prior vascular disease [8]. In another
study, in which the disease and reference groups were defined by
both eGFR cut-points and the presence and absence of
proteinuria, the authors were contacted to provide results based
on cut points of eGFR alone [19].
Data synthesis and analysis
The primary analyses involved estimating the relative risk of a
MVE and of all-cause mortality associated with a 30% lower
eGFR. (Among 20536 participants in the MRC/BHF Heart
Protection Study [24], this was the approximate proportional
difference in mean baseline eGFR between those with an eGFR of
60–89 ml/min/1.73 m
2 [mean eGFR 74 ml/min/1.73 m
2] and
$90 ml/min/1.73m
2 [mean eGFR 101 ml/min/1.73 m
2], and
between those with an eGFR 30–59 ml/min/1.73m
2 [mean
eGFR 51 ml/min/1.73m
2] and 60–89 ml/min/1.73 m
2). The
results for individual studies are presented with 99% confidence
intervals, whilst summary results are presented with 95%
confidence intervals. In order to explore the possible role of
reverse causality (ie, a history of vascular disease leading both to an
increase in risk and a reduction in eGFR), we subdivided studies
into those in populations with known vascular disease and those
which did not select individuals on the basis of prior vascular
disease (ie, studies which either excluded those with prior vascular
disease or consisted of unselected samples of the general
population, the elderly or individuals with diabetes or hyperten-
sion). We analysed prospective cohort studies, retrospective cohort
studies and randomised trials separately. To further assess the
possible bias introduces by reverse-causality we also performed
sensitivity analyses excluding studies that included individuals with
an acute illness requiring hospitalisation at baseline.
Calculating summary risk estimates for each study
Depending on the format of reporting in each study publication,
study-specific relative risks corresponding to a 30% lower eGFR
were estimated because such a decrement in eGFR is approxi-
mately equivalent to the differences between an eGFR of 90 and
60 ml/min/1.73 m
2 or between 60 and 45 ml/min/1.73 m
2,
both of which correspond to cut-offs for KDOQI CKD stages.
The relative risks for MVEs and for all-cause mortality were
calculated using one of the following methods:
i. Comparisons between two categories: the relative risk per 30%
lower eGFR (RR*) was estimated from the published relative
risk (RR) through the equation RR* = 0.7
ln(RR)/ln(a/b), where b
is the mean eGFR level in the reference group and a is the
mean eGFR level in the single comparison group.
ii. Comparisons between more than two categories: logistic
regression based on the number of subjects and events
observed in each exposure group was used to estimate the
variance-covariance matrix of the crude log odds ratios, which
was then used to estimate the approximate ‘‘floated’’ standard
error of the log odds ratio for each group (including the
reference group) [25]. For each outcome, the relative risk
associated with a 30% lower eGFR was estimated from the
slope provided by the weighted linear regression of the
published log relative risks on the (log) mean eGFR levels (with
weights equal to the reciprocal of the square of the floated
standard errors, ie, inverse variance weighted) with the
standard error of the slope corrected by dividing it by the
square root of the mean squared error (which is needed when
regression weights are known exactly rather than just
relatively) [26].
In studies that did not report mean eGFR levels for each
analysis category we assumed a normal distribution for eGFR
(since this was approximately the distribution observed in the
Heart Protection Study [24]; data not shown) and calculated
means using the conditional probability density function with the
population mean and variance (Appendix S2). In one study [27], a
log-normal distribution was assumed rather than a normal
distribution because the authors explicitly stated that the
distribution was positively skewed (the mean values in this study
therefore represent geometric means). If the mean eGFR or
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was estimated from the proportions of the population falling within
each group (Appendix S2). (The validity of this method was
confirmed by using it to compare estimated and observed eGFR
levels in the 38 studies that did report mean eGFR level in each
group [Figure S1].)
Assessing heterogeneity between studies
Given the summary log relative risk bi (and its variance vi) for
each study (see above), heterogeneity between the different studies
was assessed by calculating g(wibi
2)-g (wibi)
2/gwi (where wi =
1/vi), and testing this against a chi-squared distribution with
degrees of freedom equal to one less than the number of studies.
The ‘‘pooled’’ log relative risk across different studies was
calculated by gwibi/gwi (with variance equal to 1/gwi).
Calculating the hypothetical population attributable risk
fraction associated with reduced eGFR
In order to assess the potential impact of reduced eGFR on
major vascular events within the population, we calculated
hypothetical population attributable risk fractions (PARF) for
three categories of reduced eGFR (60-89 ml/min/1.73m
2, 30–
59 ml/min/1.73 m
2 and 15–29 ml/min/1.73 m
2) using age
specific prevalence estimates from the National Health and
Nutrition Estimation Survey (1999 to 2000) [3]. The PARF for
the jth eGFR category (j=1,2,3) is given by pj(RRj – 1)/(1 +
gpi(RRi-1)) where pj is the proportion of the population falling
into the jth eGFR category and RRj is the relative risk for the jth
eGFR category compared with the reference group (eGFR
$90 ml/min/1.73 m
2). The overall PARF associated with
reduced eGFR (,90 ml/min/1.73 m
2) is then calculated by the
sum of the PARFs for each eGFR category.
This study was conducted at the Clinical Trial Service Unit,
University of Oxford and required no external funding.
Results
Figure 1 summarizes the search retrieval process. Out of 11981
abstracts reviewed, 198 papers were retrieved for further
examination, of which 80 met the inclusion criteria, with 5 more
being identified from the reference lists. Contained within these 85
manuscripts was information relating to 90 different studies. Mean
Figure 1. Results of the literature search.
doi:10.1371/journal.pone.0025920.g001
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information was provided to allow their estimation) in 81 of these
studies (58 cohort studies [28 prospective and 30 retrospective]
and 23 randomised controlled trials (Table S1).
Fifty studies (25 prospective cohort studies, 10 retrospective
cohort studies and 15 trials) comprising a total of over 2 million
individuals had assessed the relationship between eGFR and the
risk of a major vascular event (MVE). The weighted mean (SD)
eGFR in the studies’ reference groups (1.6 million individuals,
78% of the sample) was 85 ml/min/1.73 m
2 (14 ml/min/
1.73 m
2). A graded relationship was observed across the different
studies with lower eGFR levels consistently related to higher MVE
risk, at least down to about 25–30 ml/min/1.73m
2 (Figure 2).
In studies among people without prior vascular disease, each
30% lower eGFR level was associated with a 29% increase in the
risk of a MVE (RR 1.29 [95% CI 1.28 to 1.30]: Figure 3). Similar
estimates were obtained from the prospective cohort studies (RR
1.31 [95% CI 1.28 to 1.34]) and retrospective cohort studies
(RR1.29 [95% CI 1.29 to 1.30]) but the randomised controlled
trials yielded a slightly lower relative risk per 30% lower eGFR
(RR 1.19 [95%CI 1.15 to 1.23]). There was substantial
heterogeneity between the results of the different prospective
cohort studies and randomised trials (Figure 3). The relative
strength of the relationship between lower eGFR and risk of a
MVE was similar among people with prior vascular disease (RR
1.26 [95% CI 1.23 to 1.28] per 30% lower eGFR: Figure 3). As in
populations without vascular disease, the results were not
substantially different in the different types of study examined
(RR per 30% lower eGFR: 1.25 [95% CI 1.18 to 1.32] in
prospective cohort studies, 1.34 [95% CI 1.30 to 1.38] in
retrospective cohort studies and 1.20 [95% CI 1.17 to 1.23] in
randomised controlled trials: Figure 3). There was significant
heterogeneity between the results of the individual prospective
cohort studies and individual retrospective cohort studies. In
contrast, there was no significant heterogeneity between the results
of the different randomised trials (Figure 3). Eight of the 26 studies
assessing MVEs among people with known prior vascular disease
included individuals with an acute illness requiring hospitalisation
at baseline (Table S1)). Excluding these studies did not materially
alter the results (RR per 30% lower eGFR 1.28 [95% CI 1.25–
1.31]).
Sixty seven studies (19 prospective cohort studies, 31 retrospec-
tive cohort studies and 17 trials) comprising a total of 4.9 million
individuals assessed the relationship between eGFR and all-cause
mortality. Among these studies, 3.7 million individuals (76% of all
participants) were included in the reference groups, in which the
weighted mean (SD) eGFR across the studies was 85 ml/min/
1.73 m
2 (14 ml/min/1.73 m
2). As was the case in analyses of
MVEs, a graded relationship was observed between lower eGFR
levels and progressively higher all-cause mortality risks (Figure 2b).
In studies among people without prior vascular disease, a 30%
lower eGFR level was, on average across the range studied,
associated with a 31% increase in the risk of death from any cause
(RR 1.31 [95% CI 1.31 to 1.32: Figure 4). The estimated RR per
30% lower eGFR was comparable across the different study
designs (1.26 [95% CI 1.24 to 1.28] in prospective cohort studies,
1.32 [95% CI 1.31 to 1.32] in retrospective cohort studies and
1.29 [95% CI 1.17 to 1.42] in randomised controlled trials).
Within the prospective and retrospective cohort studies, however,
there was substantial heterogeneity between the results from the
individual studies (Figure 4). In studies of individuals with prior
vascular disease a 30% lower eGFR was associated with 23%
increase in the risk of death from any cause (RR 1.23 [95% CI
1.22 to 1.23]: figure 4). A slightly higher relative risk was observed
in prospective cohort studies (1.36 [95% CI 1.30 to 1.41]) than in
the retrospective cohort studies (1.22 [95% CI 1.22 to 1.23]) or the
randomised controlled trials (1.23 [95% CI 1.20 to 1.26]).
Substantial heterogeneity was observed between the results from
the different prospective and retrospective cohort studies, but not
between the results from the trials (Figure 4). Among the 50 studies
assessing all cause mortality in people with prior vascular disease,
24 included individuals who were acutely unwell at baseline (Table
S1). Results were similar when these studies were excluded (RR
per 30% lower eGFR 1.24 [95 CI 1.24–1.25]).
Figure 2. Relationship between eGFR and risk of major vascular events and all-cause mortality. Relative risks are shown on the log
scale. The area of each plotting symbol is proportional to the amount of statistical information (i.e. it is inversely proportional to the variance of the
floated log odds ratio). The dashed lines represent the best local polynomial regression fits.
doi:10.1371/journal.pone.0025920.g002
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Figure 3. Meta-analysis of the association between eGFR and major vascular events.
doi:10.1371/journal.pone.0025920.g003
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Figure 4. Meta-analysis of the association between eGFR and all-cause mortality.
doi:10.1371/journal.pone.0025920.g004
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A large number of population-based studies have reported
associations between estimated GFR and particular outcomes, but
they have employed a wide variety of methods making it difficult
to summarise the results of such studies quantitatively. In this
meta-analysis, we have used a novel method of statistical synthesis
and have shown that there are inverse relationships between
proportional differences in baseline eGFR and the risks of all cause
mortality and of major vascular events. Although there is
substantial heterogeneity among the different studies, overall the
studies indicate that a 30% lower eGFR was associated with
approximately 20–30% greater risk of each outcome. The strength
of the associations, as estimated by relative risks, did not appear to
be influenced strongly by whether individuals already had a
history of vascular disease, suggesting that these associations are
unlikely to be attributable to reverse causality (whereby a history of
vascular disease leads both to reduced eGFR and a higher risk of
recurrence). Although we could not assess the relationship between
eGFR and mortality at different ages using the pooled data, age-
specific results were made available by the authors of one very
large study of eGFR and all-cause mortality (the Veterans Affairs
Study;[8]). The relative strength of the relationship between eGFR
and all-cause mortality decreased with older age. For example,
among those without prior vascular disease, the RR (95% CI) of
death associated with a 30% lower eGFR was 1.43 (1.39 to 1.46) at
ages 45-54 and 1.24 (1.22 to 1.27) at ages 75–84 (Figure S2).
However, since older people have a higher annual risk of death,
the absolute increase in deaths associated with lower eGFR is
substantially greater among the elderly: for example, among
people aged 45-54, a 30% lower eGFR was associated with about
50 extra deaths per 10 000 people per year as compared to about
100 extra deaths per 10 000 people per year among people aged
75–84. Similarly the absolute relevance of eGFR to all-cause
mortality risk was greater in people with prior CVD.
In weighing the potential importance of these findings, several
sources of bias need to be considered: (i) bias due to the limitations
of data extracted from published data; (ii) bias due to methods of
estimated GFR; and (iii) bias due to regression dilution. These
biases are possible explanations for between-study heterogeneity in
relative risk estimates, but also have the potential to influence the
shape and strength of the overall associations observed.
Although our methods were designed to minimise the errors
introduced by differences between studies in laboratory calibra-
tion, or in the particular statistical measures of association that
were reported, there are nevertheless several other ways in which
the use of summary data from published reports might introduce
bias. For example, there was little uniformity in the definition of
MVEs, with some studies considering only myocardial infarction,
some just stroke, and others a composite of several types of
vascular event (Table S1). Such variations could have resulted in
heterogeneity if, as is plausible, the strengths of any associations
with eGFR vary between different vascular outcomes. Similarly,
since only 3 studies assessed vascular and non-vascular mortality
separately [17–19], our analysis examined only all-cause mortality.
Consequently, variation between studies in the proportions of
deaths attributable to vascular disease could well result in
heterogeneity in associations between eGFR and death from any
cause. Furthermore, there were substantial differences between the
studies in the extent to which adjustment was made for
confounding. In many of the studies, particularly the retrospective
cohorts, adjustment was made only for the presence of co-morbid
disease abstracted from health care records, which might have led
to an overestimation of the risks of MVE and death associated with
lower eGFR because of residual confounding. However, some of
the studies might equally have underestimated the relevance of
eGFR by adjusting for factors, such as blood pressure, which are
likely to be part of the mechanism by which reduced GFR might
increase the risk of vascular disease and death, (ie, the ‘‘causal
pathway’’).
All of the studies in this meta-analysis used a creatinine-based
method for estimating GFR. Other studies have shown that eGFR
estimates are only weakly related to true GFR among individuals
with eGFR in excess of about 60 ml/min/1.73 m
2, so above this
level there is likely to be misclassification of individuals between
comparison and reference groups [28]. The anticipated effect of
this would be to flatten the dose response curve among those with
higher eGFR and would also result in underestimation of the
strength of the relationships between true GFR and risk of vascular
disease and all-cause mortality [29].
Regression dilution bias may also have resulted in distortion of
the true dose-response risk-relationships [30]. To investigate this,
eGFR estimates over about 5 years were examined among 7697
individuals allocated placebo in the MRC/BHF Heart Protection
Study (HPS) [24]. Among individuals with baseline eGFR below
70 ml/min/1.73 m
2, no regression to the mean upon re-
measurement was observed (slope of follow-up log eGFR regressed
on baseline log eGFR = 1.06 [Figure S3]), whereas substantial
regression to the mean was observed (slope=0.65) among those
with higher eGFR at baseline. Considered together, the non-
uniform effect of correction for regression to the mean might be to
straighten somewhat the inflection that is suggested among those
with higher levels of eGFR in Figure 2.
Until recently, attempts to summarise the available data
assessing the relationships between eGFR and important outcomes
have been only semi-quantitive [16,31]. However, a collaborative
meta-analysis of 21 general population studies that were able to
provide detailed individual data, published in June 2010 by the
Chronic Kidney Disease Prognosis Consortium, reported relations
between predefined categories of eGFR and albuminuria and 45
584 deaths from any cause and 9637 deaths due to cardiovascular
disease [32]. Lower eGFR and increasing level of albuminuria
were each independently associated with an increase in the risk of
both outcomes [32]. However, among those with preserved eGFR
(i.e. eGFR .60 ml/min/1.73 m
2), the relationship between
eGFR and these outcomes was flat, possibly – as described above
– due to the weak relationship between creatinine and true GFR,
and regression dilution bias. Since the CKD prognosis consortium
included only 5 of the general population studies included in our
meta-analysis, our results complement these findings by demon-
strating the consistency of the associations across a large number of
studies including populations with and without prior vascular
disease.
The present study cannot determine whether any of the
observed associations are causal, although an association between
reduced GFR and vascular disease is suggested by studies
indicating that minor degrees of renal impairment following
kidney donation result in permanent increases in blood pressure
[33;34]. If it is assumed that the relationships are causal, how large
might the contribution of reduced renal function to the risk of
vascular disease in the general population be? In order to assess
this hypothetically, prevalence data from the National Health and
Nutrition Estimation Survey [3] were used to calculate population
attributable risk fractions (PARFs) of MVEs for three categories of
reduced eGFR (60–89 ml/min/1.73 m
2, 30–59 ml/min/1.73 m
2
and 15–29 ml/min/1.73 m
2) in both middle and old age (ie the
proportion of vascular events that would have been avoided if the
risk among those with reduced eGFR was the same as among
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2). Figure 5 indicates
that if each category of reduced eGFR was causally associated with
about a 25% increase in the risk of a MVE, the combined PARF
associated with an eGFR ,90 ml/min/1.73 m
2 would be about
10% among those aged 40–59 years rising to over 20% among
those aged over 70 years. Since the incidence of vascular events is
much higher among older people, the absolute number of excess
vascular events potentially attributable to renal impairment would
be substantially higher at older ages. Based on US death rates in
2005, we might expect 10 excess vascular deaths per 100,000
people per year among those aged 45–54 years compared to 400
excess vascular deaths per 100,000 people per year among those
aged 75–84 years.
This meta-analysis suggests that a 30% lower eGFR is
associated with a 20–30% increase in the risk both of major
vascular events and of death from any cause which, if causal,
would imply that up to 10% of vascular events in middle age and
20% in old age might be attributable to age-related changes in
renal function. Given the potential size of the contribution of age-
related loss of renal function to public health, the many
uncertainties about the nature and strength of relationships
between eGFR and individual vascular outcomes and cause-
specific mortality in various populations requires further study.
Supporting Information
Figure S1 Comparison of actual vs estimated mean
eGFR levels.
(PDF)
Figure S2 Age-specific association between eGFR and
all-cause mortality in the Veterans Affairs Study.
(PDF)
Figure S3 Mean follow-up eGFR level by percentile of
the baseline distribution among 7697 placebo patients in
the Heart Protection Study (follow-up 4-5 years later).
(PDF)
Table S1 Characteristics of included studies.
(PDF)
Appendix S1 PubMed search conducted on 1st Septem-
ber 2008.
(PDF)
Appendix S2 Statistical appendix.
(PDF)
Acknowledgments
We would like to thank Dr. A. O’Hare, Professor M. Sarnak, Dr. D.
Weiner, Dr. F. Biancari, Dr. A. Go, Dr. M. Tonelli and Dr. T. Craven
who provided data specifically for this study and to Professors R. Collins
and J. Armitage for providing the eGFR measurements from the Heart
Protection Study.
Author Contributions
Conceived and designed the experiments: MM MJL CB. Performed the
experiments: MM JE CB. Analyzed the data: MM JE. Wrote the paper:
MM JE MJL C-PW CB.
References
1. Foley RN, Parfrey PS, Sarnak MJ (1998) Clinical epidemiology of cardiovascular
disease in chronic renal disease. Am J Kidney Dis 32: S112–9.
2. U.S. Renal Data System, National Institutes of Health (NIH) National Institute
of Diabetes and Digestive and Kidney Diseases (2008) USRDS 2008 Annual
Data Report: Atlas of End-Stage Renal Disease in the United States. Volume 2.
Bethesda: NIH.
3. Coresh J, Byrd-Holt D, Astor BC, Briggs JP, Eggers PW, et al. (2005) Chronic
kidney disease awareness, prevalence,and trends among U.S. adults, 1999 to
2000. J Am Soc Nephrol 16: 180–8.
4. Muntner P, He J, Hamm L, Loria C, Whelton PK (2002) Renal Insufficiency
and Subsequent Death Resulting from Cardiovascular Disease in the United
States. J Am Soc Nephrol 13: 745.
5. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney
disease and the risks of death, cardiovascular events, and hospitalization.
N Engl J Med 351: 1296–305.
6. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, et al. (2004) Chronic
kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a
pooled analysis of community-based studies. J Am Soc Nephrol 15: 1307–15.
7. Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr., et al. (2006)
Cardiovascular Outcomes in High-Risk Hypertensive Patients Stratified by
Baseline Glomerular Filtration Rate. Ann Intern Med 144: 172–80.
8. O’Hare AM, Bertenthal D, Covinsky KE, Landefeld CS, Sen S, et al. (2006)
Mortality risk stratification in chronic kidney disease: one size for all ages? J Am
Soc Nephrol 17: 846–53.
9. Knight EL, Rimm EB, Pai JK, Rexrode KM, Cannuscio CC JE, et al. (2004)
Kidney dysfunction, inflammation, and coronary events: a prospective study.
J Am Soc Nephrol 15: 1897–903.
10. Ninomiya T, Kiyohara Y, Kubo M, Tanizaki Y, Doi Y, et al. (2005) Chronic
kidney disease and cardiovascular disease in a general Japanese population: the
Hisayama Study. Kidney Int 68: 228–36.
11. Wannamethee SG, Shaper AG, Lowe GD, Lennon L, Rumley A, et al. (2006)
Renal function and cardiovascular mortality in elderly men: the role of
inflammatory, procoagulant, and endothelial biomarkers. Eur Heart J 27:
2975–81.
12. Nickolas TL, Khatri M, Boden-Albala B, Kiryluk K, Luo X, et al. (2008) The
association between kidney disease and cardiovascular risk in a multiethnic
cohort: findings from the Northern Manhattan Study (NOMAS). Stroke 39:
2876–9.
13. Deo R, Fyr CL, Fried LF, Newman AB, Harris TB, et al. (2008) Kidney
dysfunction and fatal cardiovascular disease--an association independent of
atherosclerotic events: results from the Health, Aging, and Body Composition
(Health ABC) study. Am Heart J 155: 62–8.
14. Mielniczuk LM, Pfeffer MA, Lewis EF, Blazing MA, de Lemos JA, et al. (2008)
Estimated glomerular filtration rate, inflammation, and cardiovascular events
after an acute coronary syndrome. Am Heart J 155: 725–31.
15. Coresh J, Astor B, McQuillan G, Kusek J, Greene T, et al. (2002) Calibration
and random variation of the serum creatinine assay as critical elements of using
equations to estimate glomerular filtration rate. Am J Kidney Dis 39: 920–9.
Figure 5. Hypothetical age-specific estimates of the population
attributable risk fraction for major vascular events associated
with reduced eGFR.
doi:10.1371/journal.pone.0025920.g005
Meta Analysis of eGFR, Death and Vascular Disease
PLoS ONE | www.plosone.org 8 October 2011 | Volume 6 | Issue 10 | e2592016. Di Angelantonio E, Danesh J, Eiriksdottir G, Gudnason V (2007) Renal function
and risk of coronary heart disease in general populations: new prospective study
and systematic review. PLoS Med 4: e270.
17. Fried LF, Katz R, Sarnak MJ, Shlipak MG, Chaves PH, et al. (2005) Kidney
function as a predictor of noncardiovascular mortality. J Am Soc Nephrol 16:
3728–35.
18. Irie F, Iso H, Sairenchi T, Fukasawa N, Yamagishi K, et al. (2006) The
relationships of proteinuria, serum creatinine, glomerular filtration rate with
cardiovascular disease mortality in Japanese general population. Kidney Int.
2006; 69: 1264–71.
19. Wen CP, Cheng TY, Tsai MK, Chang YC, Chan HT, et al. (2008) All-cause
mortality attributable to chronic kidney disease: a prospective cohort study based
on 462 293 adults in Taiwan. Lancet 371: 2173–82.
20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, et al. (1999) A More
Accurate Method To Estimate Glomerular Filtration Rate from Serum
Creatinine: A New Prediction Equation. Ann Intern Med 130: 461–70.
21. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum
creatinine. Nephron 16: 31–41.
22. Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, et al. (2004) Effect of
pravastatin on cardiovascular events in people with chronic kidney disease.
Circulation 110: 1557–63.
23. Weiner DE, Tighiouart H, Stark PC, Amin MG, MacLeod B, et al. (2004)
Kidney disease as a risk factor for recurrent cardiovascular disease and mortality.
Am J Kidney Dis 44: 198–206.
24. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart
Protection Study of cholesterol lowering with simvastatin in 20536 high-risk
individuals: a randomised placebo-controlled trial. Lancet 360(9326): 7–22.
25. Plummer M (2004) Improved estimates of floating absolute risk. Stat Med 23:
93–104.
26. Thompson SG, Sharp SJ (1999) Explaining heterogeneity in meta-analysis: a
comparison of methods. Stat Med 18: 2693–708.
27. Wright R, Scott R, Guy S, Herzog CA, Albright RC at al (2002) Acute
Myocardial Infarction and Renal Dysfunction: A High-Risk Combination. Ann
Intern Med 137: 563–570.
28. Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, et al. (2004) Using
serum creatinine to estimate glomerular filtration rate: accuracy in good health
and in chronic kidney disease. Ann Intern Med 141: 929–37.
29. Duffy SW, Rohan TE, Day NE (1989) Misclassification in more than one factor
in a case-control study: a combination of Mantel-Haenszel and maximum
likelihood approaches. Stat Med 8: 1529–36.
30. Clarke R, Shipley M, Lewington S, Youngman L, Collins R, et al. (1999)
Underestimation of risk associations due to regression dilution in long- term
follow-up of prospective studies. Am J Epidemiol 150: 341–53.
31. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, et al. (2005) Chronic
kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial
Transplant 20: 1048–56.
32. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al.
(2010) Association of estimated glomerular filtration rate and albuminuria with
all-cause and cardiovascular mortality in general population cohorts: a
collaborative meta-analysis. Lancet 375: 2073–2081.
33. Boudville N, Prasad GV, Knoll G, Muirhead N, Thiessen-Philbrook H (2006)
Meta-analysis: risk for hypertension in living kidney donors. Ann Intern Med
145: 185–96.
34. Garg AX, Prasad GV, Thiessen-Philbrook HR, Ping L, Melo M, et al. (2008)
Cardiovascular disease and hypertension risk in living kidney donors: an analysis
of health administrative data in Ontaria, Canada. Transplantation 86: 399–406.
Meta Analysis of eGFR, Death and Vascular Disease
PLoS ONE | www.plosone.org 9 October 2011 | Volume 6 | Issue 10 | e25920